Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Increases Medicare Rx Plan Flexibility On Eve Of Application Deadline

Executive Summary

The Centers for Medicare & Medicaid Services' flexible stance on Part D plan design may have the unintended consequence of flooding the market with too many choices for beneficiaries

You may also be interested in...



Marketing Part D As Insurance Is Key To Success, PacifiCare Exec Says

Medicare Part D plan sponsors that can persuade seniors to view the drug benefit as insurance will be the most sucessful, PacifiCare Corporate VP-Public Policy Janet Newport said

Employers May Favor “Private Label” Plan Option Under Part D –Consultant

Contracting with a private label prescription drug plan or Medicare Advantage drug plan may be the best option for employers under Medicare Part D, Milliman Associate Actuary Frank Kopenski said at the Pharmaceutical Benefit Management Institute conference in Scottsdale, Ariz. March 31

Employers May Favor “Private Label” Plan Option Under Part D –Consultant

Contracting with a private label prescription drug plan or Medicare Advantage drug plan may be the best option for employers under Medicare Part D, Milliman Associate Actuary Frank Kopenski said at the Pharmaceutical Benefit Management Institute conference in Scottsdale, Ariz. March 31

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel